Indication: It is suitable for acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, pneumonia and other respiratory tract infections, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria. This product is an oral preparation and should not be used for severe infections.

Indication: It is suitable for acute tonsillitis, pharyngitis, otitis media, sinusitis, bronchitis, pneumonia and other respiratory tract infections, urinary tract infections and skin and soft tissue infections caused by sensitive bacteria. This product is an oral preparation and should not be used for severe infections.

Indication: In recent years, many common clinical pathogens often show resistance to this product, so the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults can use it, whose CD4 lymphocyte count is ≤200/mm3 or less than 20% of the total lymphocyte count. 7. Traveler's diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Indication: In recent years, many common clinical pathogens often show resistance to this product, so the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults can use it, whose CD4 lymphocyte count is ≤200/mm3 or less than 20% of the total lymphocyte count. 7. Traveler's diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Indication: In recent years, many common clinical pathogens often show resistance to this product, so the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults can use it, whose CD4 lymphocyte count is ≤200/mm3 or less than 20% of the total lymphocyte count. 7. Traveler's diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Indication: In recent years, many common clinical pathogens often show resistance to this product, so the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults can use it, whose CD4 lymphocyte count is ≤200/mm3 or less than 20% of the total lymphocyte count. 7. Traveler's diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Indication: In recent years, many common clinical pathogens often show resistance to this product, so the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults can use it, whose CD4 lymphocyte count is ≤200/mm3 or less than 20% of the total lymphocyte count. 7. Traveler's diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Indication: In recent years, many common clinical pathogens often show resistance to this product, so the treatment of bacterial infections needs to refer to the drug sensitivity results. The main indications of this product are the following infections caused by sensitive strains: 1. Urinary tract infections caused by sensitive strains of Escherichia coli, Klebsiella, Enterobacter, Proteus mirabilis, Proteus vulgaris and Morganella. 2. Acute otitis media in children over 2 years old caused by Streptococcus pneumoniae or Haemophilus influenzae. 3. Acute exacerbation of chronic bronchitis in adults caused by Streptococcus pneumoniae or Haemophilus influenzae. 4. Intestinal infections and Shigella infections caused by sensitive strains of Shigella flexneri or sonnei. 5. This product is the first choice for the treatment of Pneumocystis carinii pneumonia. 6. For the prevention of Pneumocystis carinii pneumonia, patients with a history of at least one attack of Pneumocystis carinii disease or HIV-infected adults can use it, whose CD4 lymphocyte count is ≤200/mm3 or less than 20% of the total lymphocyte count. 7. Traveler's diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Indication: It is suitable for the following infections caused by β-lactamase-producing pathogens that are resistant to piperacillin and sensitive to this product. When used to treat mixed infections caused by bacteria that are sensitive to piperacillin alone and β-lactamase-producing bacteria that are resistant to piperacillin alone and sensitive to this product, no other antibiotics are needed. 1. Respiratory system infections: including acute bronchitis, pneumonia, acute exacerbation of chronic bronchitis, bronchiectasis and concurrent infection, etc. 2. Urinary system infections: including simple urinary system infections and complicated urinary system infections.

Indication: It is suitable for pneumonia and other lower respiratory tract infections, urinary tract infections, meningitis, sepsis, abdominal infections, pelvic infections, skin and soft tissue infections, reproductive tract infections, bone and joint infections caused by sensitive bacteria. Cefotaxime can be used as a drug of choice for infantile meningitis.